Real World Effectiveness of Antipsychotic Treatment on Functional Outcomes Over Ten Years: A National Cohort of Patients in Denmark with Schizophrenia

Ricardo Twumasi [a,b,c], Frederikke Hørdam Gronemann [c], Carsten Hjorthøj [b,d], Oliver D. Howes [a,e], Maximin Lange [a], Merete Nordentoft [b,d], Merete Osler [c,d]

[a] *King's College London Institute of Psychiatry Psychology and Neuroscience*
[b] *Copenhagen Research Center for Mental Health*
[c] *Center for Clinical Research and Prevention Copenhagen University Hospital Bispebjerg and Frederiksberg*
[d] *University of Copenhagen*
[e] *South London and Maudsley NHS Foundation Trust*

Abstract

Background Antipsychotic medications are recommended for managing schizophrenia spectrum disorders, yet their long-term effects on functional recovery remain unclear. Existing evidence is conflicting, often derived from between-subject comparisons vulnerable to confounding by indication.

Methods We conducted a nationwide register-based cohort study of 65,630 individuals with incident schizophrenia spectrum disorders in Denmark (1998-2023). We modelled antipsychotic exposure against 'productive engagement' (employment or education). We employed two distinct analytical approaches to separate causal from prognostic associations: (1) Within-subject stratified Cox models with time-varying covariates, where patients served as their own controls to eliminate time-invariant confounding; and (2) Fine-Gray competing risks models using a between-subject design with baseline exposure, accounting for mortality and emigration.

Findings Over 26.9 million person-weeks, the overall productive engagement rate was 48.2%. Integration of hospital pharmacy data revealed a 6.1% exposure misclassification bias in previous studies relying solely on community records. The primary within-subject analysis revealed significant temporal heterogeneity: medication use was associated with reduced engagement rates in the acute (0–2 years: HR 0.908) and consolidation phases (2–5 years: HR 0.946), but reversed to a positive association in the maintenance phase (5+ years: HR 1.019). In contrast, the between-subject Fine-Gray model yielded a null result (SHR 1.002, 95% CI 0.988–1.015), failing to detect these phase-specific dynamics.

Interpretation Within-subject modelling reveals that antipsychotic treatment involves a functional trade-off: it is associated with a transient reduction in engagement rates during the early 'consolidation' phase (2–5 years), followed by stabilisation and potential benefit in the maintenance phase (5+ years). The null result in standard between-subject (Fine-Gray) analysis likely reflects residual confounding by indication and exposure misclassification, highlighting the necessity of within-person designs to unmask the true stage-specific impact of pharmacotherapy on vocational recovery.

Funding None directly for this study. Danmarks Nationalbank funded the research visit that facilitated this collaboration.

Keywords: psychosis; functional outcomes; registry; big data

1. Introduction

Schizophrenia spectrum disorders (SSDs) profoundly disrupt employment and social functioning. Despite antipsychotic medications being effective for symptom control, only 32.5% of individuals with first-episode psychosis maintain employment long-term (Ajnakina et al., 2021). Current guidelines recommend continuous maintenance antipsychotic therapy based on strong evidence that discontinuation increases relapse risk (Keepers et al., 2020; Leucht et al., 2012). However, this recommendation prioritises symptomatic stability over functional outcomes, and clinicians must weigh relapse prevention against potential adverse effects that could impair work capacity (Cornblatt et al., 2011). Recent trials suggest dose reduction strategies may yield comparable or superior long-term functional outcomes despite higher initial relapse rates (Wunderink et al., 2013; Moncrieff et al., 2023).

This study builds on Stürup et al. (2023), who examined antipsychotic patterns and employment outcomes in first-episode schizophrenia using discrete exposure windows (years 2-5) and outcomes at year 6. Stürup et al. (2023) found that individuals who discontinued antipsychotics had higher odds of employment compared with continuous users. We extend this work using a rigorous methodological triangulation approach. We contrast a within-subject design (which controls for all time-invariant genetics and history) against a standard between-subject competing risks analysis. This dual approach enables us to test whether findings from standard observational models hold up when strictly controlling for unmeasured confounding factors, such as illness severity and premorbid cognitive capacity, which are typically prevalent in psychiatric epidemiology.

2. Methods

Study Design and Setting

A protocol with statistical analysis plan was uploaded to medRxiv on 2nd October 2025 (Twumasi et al., 2025). Exploratory analysis and pre-processing were carried out before protocol posting. All inferential statistics and survival analysis were completed after the pre-registration was accepted on the 3rd October 2025. Our only departure from the protocol was the decision to include all individuals rather than restrict to 18+. This was decided because the result of productive participation encompasses both employment and education, making the age restriction to 18+ unnecessary and potentially biasing against cases onset in adolescents.

We conducted a nationwide, register-based cohort study using a within-subject design. The study was carried out in Denmark, which has a tax-funded welfare system that ensures universal access to primary and hospital-based healthcare, as well as a broad social support system in cases of illness or loss of income. Further, Denmark's active labour market policies provide extensive employment support, including subsidised vocational training programmes (Pedersen et al., 2025), grants for university education, and workplace accommodations for individuals with mental health conditions.

*Corresponding author: R. Twumasi. ricardo.twumasi@kcl.ac.uk

Embedded in the Danish welfare model is equal access to public services, for example in the event of loss of earned income or illness. The system is tax-funded and systematic registration of individuals receiving benefit payments is mandatory.

The Danish Civil Registration System assigns a unique personal identification number (CPR number) to every resident at birth or upon immigration, which enables unambiguous, individual level linkage across all national administrative and health registers with complete follow-up. The registers used in the study cover every resident in Denmark without the possibility of opting out (Nordfalk and Hoeyer, 2017), thereby limiting selection bias in our cohort.

Data Sources

Data were drawn from multiple validated national registers. The Danish National Patient Register (Plana-Ripoll et al., 2025; Lynge et al., 2011) was used to identify the study cohort and all psychiatric diagnoses. Antipsychotic medication use was ascertained from the Danish National Prescription Register (NPR)(Pottegård et al., 2017), which contains detailed records of all prescriptions dispensed from community pharmacies since 1995. For the period from 2018 onwards, NPR data were supplemented with data from the Danish National Hospital Medicine Register (Sygehusmedicinregisteret, SMR)(Andersen et al., 2024), which records medications administered during hospital stays. Information on labour market status was obtained from the Danish Register for Evaluation and Marginalization (DREAM)(Hjollund et al., 2007), which contains weekly data on all public transfer payments (e.g., sickness benefits, unemployment benefits, disability pension). The DREAM register's unique weekly granularity in capturing benefit receipt, combined with Denmark's comprehensive national health registers and universal Central Person Register (CPR) number linkage system, creates a unique opportunity to examine the longitudinal association between medication patterns and labour market outcomes in schizophrenia spectrum disorders.

Data availability and guidelines

This study used Danish register data provided by Statistics Denmark. Access to data can be granted for approved research projects. All microdata were handled according to guidelines to prevent identification, including rounding counts. No additional data are publicly available.

Study Population

The source population included all individuals residing in Denmark who received a first-time diagnosis of a non-affective psychotic disorder (ICD-10 codes F20-F29). The date of the first registered F20-F29 diagnosis was defined as the cohort entry date.

To ensure complete temporal alignment between medication exposure and employment data, we restricted the cohort to individuals with index diagnosis dates between January 1, 1998, and December 31, 2023, reflecting the period for which relevant DREAM labour market affiliation data were available for this project.

Individuals were excluded if they died or emigrated within two years of cohort entry. This 2-year exclusion filter removed 1,000 patients (1.52% of cohort). Community pharmacy records (NPR) do not capture medications administered during inpatient stays, or free medication offered to patients with recent onset schizophrenia (Jensen et al., 2020), which could lead to exposure misclassification bias in our main sample. Therefore a further subgroup analysis on SMR data which includes the first two years of prescriptions for members of the cohort first diagnosed after 2018 was completed.

Study Variables

Antipsychotic Exposure

The primary exposure was antipsychotic medication use, modelled as a time-varying variable. For the period 1998-2017, exposure was based on filled prescriptions in the NPR (ATC code N05A, excluding lithium N05AN01). For the period 2018-2023 sensitivty analysis, exposure was based on an integrated record of NPR prescriptions and SMR in-hospital prescriptions Andersen et al. (2024).

We calculated medication exposure duration for each prescription using Tiihonen's methodology Tiihonen et al. (2011), adapted from the original protocol used in the nationwide Finnish schizophrenia cohort study. This approach models individual prescription coverage periods based on package characteristics and Defined Daily Doses (DDDs) from the World Health Organisation ATC/DDD Index 2025 (WHO, 2025)

For each prescription, exposure duration in days was calculated as:

$$\text{Exposure}_{\text{days}} = \left(\frac{\text{Volume} \times \text{strnum}}{\text{tablets per DDD}}\right) \times 1.15 + \text{Grace Period} \tag{1}$$

The 1.15 multiplier accounts for dosing variability and patient stockpiling behavior Tiihonen et al. (2011). Grace periods differed by formulation: 14 days for oral medications and 28 days for long-acting injectable (LAI) depot formulations, reflecting typical administration intervals. Calculated durations were capped at 7-180 days per prescription to exclude implausible values.

Person-weeks were classified as *AP use* if they fell within an active prescription coverage period, and *no AP use* otherwise. This duration-based approach provides more accurate exposure estimation than simple unit-counting methods, particularly for LAI formulations where package size does not reflect duration of action.

Antipsychotics were further categorised by generation: *first-generation* (typical) antipsychotics included ATC codes N05AA, N05AB, N05AC, N05AD, N05AF, and N05AG; *second-generation* (atypical) antipsychotics included N05AE, N05AH, N05AL, and N05AX. Clozapine (N05AH02) was analysed separately given its unique indication for treatment-resistant schizophrenia. LAI formulations were identified through product name keyword matching.

When multiple medications were dispensed concurrently within a person-week, classification prioritised clozapine, followed by LAI, then oral antipsychotics. Polypharmacy was defined as concurrent use of both a first-generation and a second-generation antipsychotic within the same person-week, representing cross-class combination therapy. Medication switching was defined as any transition between exposed and unexposed states during follow-up, with individuals contributing person-time to both states classified as switchers.

Hospital Medication Data Integration

For the subcohort diagnosed from 2018 onwards (N=14,190, 30% of total cohort), we integrated hospital pharmacy records from the SMR Andersen et al. (2024) to eliminate exposure misclassification bias in the early post-diagnosis period. SMR data contained 1,218,821 antipsychotic prescriptions (ATC code N05A minus lithium). The SMR contained true dose strength data (99.99% complete) enabling more accurate DDD calculations using the following equation:

$$\text{total_ddd}_{\text{true}} = \frac{\text{dose_volume} \times \text{dose_strength}}{\text{WHO DDD}} \tag{2}$$

where grace period = 14 days (oral) or 28 days (LAI).

Outcome Measures

The primary outcome was 'productive engagement', a time-varying binary variable at the person-week level indicating whether an individual was engaged in competitive employment, formal education, or a vocational training program. The operationalisation was based on a hierarchical classification of weekly labour market affiliation, with specific codes from the DREAM used to define each state (see Supplementary Table 1 Appendix A for full details).

Covariates

The within-subject design controlled for all time-invariant confounders. The analysis adjusted for two key time-varying covariates that were updated at each person-week observation. Age and recent hospital discharge. Finally, a baseline time-invariant covariate, gender (legal sex represented by CPR number), was also included in all models. Time-varying covariate adjustment was implemented using the counting process formulation of Cox proportional hazard models within a person-week panel data structure. Each individual contributed multiple observations (one per week of follow-up), with covariate values updated at each time point. The models used within-person stratification which conditions on the individual-level baseline hazard and effectively controls for all time-invariant unmeasured confounders (equivalent to a fixed-effects approach).

Statistical Analysis

We employed methodological triangulation (Lawlor et al., 2017) using multiple analytical approaches with different assumptions to allow us to attempt to understand potential associations beyond what a single method could offer. This strategy addresses the fundamental challenge that all observational pharmacoepidemiologic analyses are vulnerable to unmeasured confounding, with different methods susceptible to different biases. By examining whether associations persist across methods with non-overlapping assumptions. Our triangulation strategy combined: (1) within-subject stratified Cox models controlling for time-invariant confounding through self-comparison, (2) time-stratified analyses characterising temporal heterogeneity in medication effects, (3) lagged exposure analyses addressing reverse causation and delayed effects, and (4) Fine-Gray competing risks models (Fine and Gray, 1999) accounting for mortality and emigration as competing events.

Primary Analysis: Within-Subject Stratified Cox Models

The primary analysis was restricted to 50,440 individuals who contributed person-time to at least two different antipsychotic exposure categories (i.e., "switchers"), enabling within-subject comparisons. We used stratified Cox proportional hazards models to estimate hazard ratios (HRs) and 95% confidence intervals (CIs) for the association between changes in antipsychotic exposure status and productive engagement transitions. In this model, each individual serves as their own control, comparing rates of productive engagement during medication-exposed versus unexposed weeks within the same person. This design eliminates confounding from all time-invariant factors including genetics, childhood adversity, baseline cognitive ability, and premorbid functioning.

This within-subject design requires patients to have variation in medication status during follow-up; 15,190 individuals (23.14%) with invariant medication patterns were excluded from Cox models but retained for descriptive analyses. Non-switchers could represent clinically distinct subgroups (severe treatment-adherent patients versus treatment-refusing individuals), with exclusion potentially limiting generalisability to patients with stable medication patterns.

Time-Stratified Analysis

The proportional hazards assumption underlying Cox models requires that hazard ratios remain constant over follow-up time. We assessed this assumption using Schoenfeld (1982) residuals tests for all models. In register-based studies of this magnitude, Schoenfeld tests typically reject the null hypothesis of proportional hazards even with minor deviations, due to the substantial statistical power afforded by large sample sizes. We therefore treated statistically significant violations as an indication of potentially meaningful temporal heterogeneity warranting further investigation through time-stratified analyses, rather than as evidence that Cox models are fundamentally unsuitable.

We computed time-stratified Cox models as the analytical approach when PH violations were detected. The 10-year follow-up was divided into three clinically meaningful periods from first diagnosis date (index date): 0-2 years (acute/early recovery phase), 2-5 years (consolidation phase), and 5+ years (long-term maintenance phase). Separate Cox models were fitted within each stratum, allowing hazard ratios to vary across periods while maintaining within-person control for time-invariant confounding. This approach provides period-specific effect estimates characterising how medication-employment associations evolve across the recovery trajectory.

Secondary Analysis: Fine-Gray Competing Risks (Between-Subject)

To provide a prognostic benchmark comparable to standard observational literature, we employed Fine-Gray subdistribution hazard models (Fine and Gray, 1999; Austin and Fine, 2017). Critically, unlike the primary within-subject Cox models, the Fine-Gray analysis was a between-subject design using baseline exposure (medication status at first diagnosis) and baseline covariates (age, gender), treating death and emigration as competing events that preclude productive engagement. This model estimates the cumulative probability of employment for the full cohort (N=65,630) but does not control for unmeasured time-invariant confounding or treatment switching, these are vulnerabilities that the within-subject Cox design eliminates. We interpreted discrepancies between these models through the lens of causal hierarchy: the within-subject Cox model was prioritised for etiological inference due to its superior control for unmeasured confounding, while the Fine-Gray model served as a 'real-world' prognostic reference reflecting the combined impact of treatment assignment, adherence patterns, and selection bias inherent in standard population comparisons.

Sensitivity Analyses

For the 2018+ subcohort with hospital pharmacy data availability (N=14,190), we compared employment outcomes under three medication exposure definitions: (1) community pharmacy only, (2) hospital pharmacy only, and (3) combined community and hospital coverage. This quantifies exposure misclassification bias magnitude from incomplete medication ascertainment during hospitalisation periods when community pharmacy records underestimate treatment intensity.

We examined effect heterogeneity across 8 dimensions (27 strata total): gender, age at diagnosis, geographic region, diagnosis subtype, medication adherence, hospitalisation type (inpatient/outpatient/emergency), and SMR data availability (pre-2018 vs 2018+).

Multiple Testing Correction

Benjamini-Hochberg (Benjamini and Hochberg, 1995) False Discovery Rate correction at the 5% threshold was applied to exploratory subgroup and sensitivity analyses examining effect heterogeneity across clinical and demographic strata.

Six Cox proportional hazards models were fitted to examine different aspects of antipsychotic medication effects on productive engagement. Model 1 examined any antipsychotic use versus no use, adjusting for age, recent hospital discharge, and gender. Model 2 assessed antipsychotic polypharmacy versus monotherapy or no treatment, with the same covariate adjustment. Model 3 evaluated a four-level medication type classification (No AP, Clozapine, LAI, Oral AP) incorporating time-varying covariates for age and recent discharge status. Model 4 tested a dose-response relationship using total exposure days (0-7 days per week) restricted to person-weeks with antipsychotic use. Model 5 attempted to fit a time-varying coefficient model (Therneau et al., 2017) which would allow the effect of antipsychotic use to vary with log-transformed follow-up time; however, this model failed to converge. We therefore fitted a model interacting medication with hospitalisation discharge, testing whether medication effects differed during the acute post-discharge period versus stable community residence.

To examine delayed medication effects and address potential reverse causation, we conducted lagged exposure analyses with 6-month, 12-month, and 24-month delays between exposure measurement and outcome assessment. By allowing time between exposure and outcome windows, these analyses reduce the risk that employment status influences medication adherence rather than vice versa, while testing the hypothesis that medication effects on employment emerge gradually over extended treatment periods.

The secondary Fine-Gray analysis (described above) estimated subdistribution hazard ratios (SHR) for comparison with the primary within-subject Cox models.

To characterise treatment complexity, we mapped all medication switches using Sankey flow diagrams, identifying transitions between medication types (first-generation only, second-generation only, clozapine, polypharmacy, and no AP use). This descriptive analysis used lag-based detection to identify week-to-week changes in medication status across the 10-year follow-up period.

Software

Data preparation was carried out in SAS (version 9.4), and Stata (version 18). Analysis was carried out using R version 4.5.1, with packages survival (Therneau, 2024), survminer (Kassambara et al., 2021), on secure Statistics Denmark servers.

Ethics

The study was approved by the Regional Data Protection Agency (P-2020-88).

3. Results

Study Cohort and Follow-up

The final analytic cohort comprised 65,630 individuals with incident schizophrenia spectrum disorders, contributing 26.9 million person-weeks of observation over a maximum analytical follow-up of 10 years (median 10.00 years, IQR: 6-10 years). By design, all estimates are representative of individuals who survived and did not emigrate during the first two years following diagnosis. Baseline characteristics are described in Table 1. The cohort was predominantly male (51.2%), with median age 30 years at first diagnosis. Notably, 82.9% reached the maximum 10-year follow-up, 81.6% received at least one antipsychotic prescription during follow-up, and 76.9% (n=50,440) were classified as medication switchers eligible for within-subject Cox models.

Table 1: Baseline Characteristics of Study Cohort

Characteristic	Overall Cohort (N=65,630)
DEMOGRAPHICS	
Age at diagnosis, median (IQR), years	30 (21–47)
Age at diagnosis, mean (SD), years	36.0 (18.9)
10–15 years, n (%)	6,940 (10.6)
15–20 years, n (%)	18,010 (27.5)
20–25 years, n (%)	13,880 (21.2)
25–30 years, n (%)	9,170 (14.0)
30–35 years, n (%)	7,020 (10.7)
35+ years, n (%)	10,610 (16.2)
Male gender, n (%)	33,620 (51.2)
Female gender, n (%)	32,000 (48.8)
PRIMARY DIAGNOSIS (ICD-10 F20-F29)	
F23 Acute transient psychotic disorders, n (%)	16,950 (25.8)
F20 Schizophrenia, n (%)	16,370 (24.9)
F22 Persistent delusional disorders, n (%)	11,120 (16.9)
F21 Schizotypal disorder, n (%)	9,280 (14.1)
F29 Unspecified nonorganic psychosis, n (%)	8,440 (12.9)
F28 Other nonorganic psychotic disorders, n (%)	1,830 (2.8)
F25 Schizoaffective disorders, n (%)	1,610 (2.5)
F24 Induced delusional disorder, n (%)	40 (0.1)
FOLLOW-UP	
Median follow-up, years (IQR)	10 (6–10)
Mean follow-up, years (SD)	7.85 (2.9)
CENSORING EVENTS	
Reached 10-year cap, n (%)	54,410 (82.9)
Death, n (%)	9,690 (14.8)
Emigration, n (%)	1,540 (2.3)
MEDICATION EXPOSURE (DURING FOLLOW-UP)	
Any antipsychotic use, n (%)	53,530 (81.6)
Never used antipsychotics, n (%)	12,110 (18.4)
Person-week coverage rate, %	40.7
Polypharmacy (≥2 AP classes), % of weeks	1.4
PRODUCTIVE ENGAGEMENT	
Overall rate during follow-up, %	48.2
BASELINE EMPLOYMENT STATUS	
Employment, n (%)	21,930 (33.4)
Unemployment, n (%)	7,660 (11.7)
Education/training, n (%)	4,230 (6.5)
Social assistance, n (%)	2,010 (3.1)
Sickness absence, n (%)	1,610 (2.5)
Retirement/pension, n (%)	960 (1.5)

Table 1 presents baseline employment status at diagnosis (33.4% employed), while the 48.2% productive engagement rate represents the longitudinal proportion across all person-weeks during follow-up, reflecting cumulative engagement over time rather than point prevalence at cohort entry.

Censoring flow patterns are visualised in Supplementary Figure A.7.

3.1. Primary Analysis (Within-Subject Cox)

Time-stratified within-subject Cox models revealed distinct phase-specific effects on productive engagement (Figure 3). Schoenfeld residual tests indicated proportional hazards violations across all models (all $p<0.001$), confirming temporal heterogeneity that warranted period-specific estimation.

In the acute phase (0–2 years, 3.1 million person-week events), antipsychotic use was associated with a 9% reduction in the rate of productive engagement (HR=0.908, 95% CI: 0.903–0.913). This negative association persisted but attenuated during the consolidation phase (2–5 years, 3.5 million events: HR=0.946, 95% CI: 0.939–0.952). Crucially, in the long-term maintenance phase (5+ years, 3.2 million events), the direction of effect reversed, with medication showing a modest positive association with employment (HR=1.019, 95% CI: 1.010–1.028).

These within-subject estimates compare medication-exposed versus unexposed person-weeks within the same individual, thereby controlling for all time-invariant confounders including genetics, premorbid functioning, and baseline illness severity. The J-shaped pattern: early negative associations reversing to late positive associations, represents the primary etiological finding of this study.

3.2. Secondary Analysis (Fine-Gray Competing Risks)

The between-subject Fine-Gray analysis, using baseline medication exposure (at first diagnosis) and adjusting only for age and gender, yielded a null result (SHR=1.002, 95% CI: 0.988–1.015). This suggests that, when viewing the population as static groups defined at diagnosis without adjusting for later switching or individual vulnerability, the 'treated' and 'untreated' cohorts achieved similar cumulative employment rates.

However, given the minimal covariate adjustment compared to the within-subject Cox models, this null finding likely reflects the cancellation of opposing forces: the drug's stage-specific pharmacological effects masked by confounding by indication, where more severely ill patients are selectively prescribed antipsychotics. Over 10-year follow-up, 38,160 individuals (69.1%) achieved productive engagement at least once, 11,730 (21.2%) remained alive but never engaged, and 550 (1.0%) experienced competing events (death or emigration).

The stark contrast between the within-subject Cox findings (HR=0.908–1.019 across periods) and the Fine-Gray null (SHR=1.002) underscores the importance of analytical design: standard between-subject comparisons fail to detect stage-specific dynamics that emerge only when patients serve as their own controls.

Exploratory Subgroup Analyses

The following exploratory analyses further characterise temporal patterns; these patterns should be interpreted as hypothesis-generating.

Cox model results are presented across four forest plots: Figure 1 (medication types by period), Figure 2 (dose-response), Figure 3 (time-stratified overall effects), and Figure 4 (lagged

exposure). Each forest plot displays hazard ratios with 95% confidence intervals, with the vertical dashed line at HR=1.0 indicating no effect.

Medication type effects exhibited temporal heterogeneity (Figure 1). During the acute phase (0-2 years), long-acting injectables showed the strongest negative associations (LAI: HR=0.691, 95% CI: 0.679-0.705), while clozapine (HR=0.903, 95% CI: 0.880-0.927) and oral antipsychotics (HR=0.828, 95% CI: 0.823-0.832) showed intermediate effects. All three medication types reversed to positive associations during consolidation (2-5 years), with clozapine showing the strongest positive association (HR=1.236, 95% CI: 1.210-1.261). The late phase (5+ years) showed a second reversal to modest negative associations across all formulations (HRs 0.947-0.964).



Figure 1: **Medication type effects vary dramatically across follow-up periods (within-subject analysis).** Hazard ratios from within-person stratified Cox models comparing medication-exposed versus unexposed person-weeks within the same individual.

Dose-response analyses among person-weeks with antipsychotic exposure revealed essentially null findings across all temporal periods (Figure 2). Hazard ratios per additional day of weekly coverage ranged from 0.989 to 1.000 across periods (95% CIs extremely tight due to sample sizes exceeding 2-4 million person-weeks per period), with no clinically meaningful dose-response gradient. The absence of dose-response effects suggests that medication presence matters more than coverage intensity for employment outcomes, consistent with threshold effects rather than linear dose-response relationships. Note that these dose-response analyses were restricted to person-weeks with antipsychotic exposure, examining intensity effects within treated periods; this does not contradict differential effects between medication categories or between exposed versus unexposed states observed in time-stratified models.



Figure 2: **Dose-response analysis reveals minimal incremental effects of medication coverage intensity.**



Figure 3: **Time-stratified hazard ratios reveal temporal heterogeneity (within-subject stratified analysis).** Each patient serves as their own control, eliminating time-invariant confounding.

Medication Exposure Patterns

Using Tiihonen methodology, antipsychotic coverage was observed in 40.65% of all person-weeks, with second-generation agents predominating (32.41%).

Sensitivity Analysis 1: Lagged Exposure Effects

Lagged exposure analyses testing temporal delays between medication exposure and employment outcomes revealed consistent negative associations across all delay periods, though with temporal attenuation suggesting medication-employment relationships evolve with treatment duration (Figure 4). At 6-month lag (13.9 million person-weeks), medication exposure 6 months prior associated with modest reduced engagement (HR=0.982, 95% CI: 0.979-0.986). The 12-month lag demonstrated the weakest association (HR=0.971, 95% CI: 0.967-0.975). At 24-month lag, the association remained negative but attenuated to the 6-month level (HR=0.984, 95% CI: 0.980-0.989, 16.0 million person-weeks).

The weakest association at 12-month lag aligns with time-stratified findings that medication-employment associations attenuate gradually over the 2–5 year consolidation period. The persistence of negative associations across all lag periods argues against reverse causation (unemployment triggering medication initiation) and is consistent with delayed medication effects that attenuate gradually as functional recovery trajectories unfold.



Figure 4: **Lagged exposure analysis reveals persistent negative associations (within-subject analysis).** Negative associations persist across 6-, 12-, and 24-month lag periods, suggesting findings are not fully explained by reverse causation.

3.3. SMR Hospital Medication Integration: Quantifying Exposure Misclassification Bias

For the 2018+ subcohort with hospital pharmacy data availability (N=14,190), integration of Sygehusmedicinregisteret (SMR) records with community prescriptions substantially reduced exposure misclassification bias. Community pharmacy coverage alone captured 26.69% of person-weeks (1,173,836 weeks), while SMR hospital pharmacy captured an additional 14.94% (657,012 weeks). Combined community and SMR coverage reached 33.25% (1,465,012 weeks), yielding

an absolute coverage gain of 6.56% (291,176 person-weeks) and relative increase of 24.6%. Notably, 291,176 weeks (44.3% of SMR coverage, 6.56% of all 2018+ person-weeks) had SMR-only coverage with no concurrent community dispensing, representing medication exposure periods that would have been misclassified as unexposed under community pharmacy data alone, particularly during early post-diagnosis hospitalisation periods.

Cox models comparing exposure definitions quantified the resulting bias. community only methodology yielded HR=0.96 (95% CI: 0.95-0.96), while combined community and SMR methodology strengthened the association to HR=0.90 (95% CI: 0.89-0.91), demonstrating 6.09% exposure misclassification bias (HR ratio: 0.96/0.90=1.067). Relying solely on community pharmacy records systematically underestimates medication-employment associations by failing to capture hospital-administered medications during acute treatment episodes. SMR integration eliminates this bias for the 2018+ cohort, providing complete medication ascertainment across hospital and community settings (Figure 5).

This 6% bias is particularly problematic for the early post-diagnosis period when hospitalisation rates are highest. Among 1,218,821 SMR prescriptions, 28,033 (2.3%) were long-acting injectables, confirming the importance of SMR for capturing depot antipsychotics initiated during inpatient stays. For pharmacoepidemiologic studies of psychotic disorders, these findings demonstrate that community pharmacy data alone systematically underestimate medication exposure during treatment periods, biasing effect estimates toward the null.



Figure 5: **SMR hospital medication integration reveals 6.09% exposure misclassification bias.**

Overall Cox Models (Supplementary Materials)

Overall pooled Cox models (HR=1.08 for AP use, HR=0.70 for polypharmacy) are provided in A.8 but should be interpreted with caution. Severe proportional hazards violations ($p<0.0001$) indicate these estimates mask temporal heterogeneity, averaging across periods with divergent effects (0-2yr: HR=0.908, 2-5yr: HR=0.946, 5+yr: HR=1.019). Given these violations, the polypharmacy estimate (HR=0.70) should not be interpreted as a stable treatment effect; time-stratified analyses provide more reliable period-specific estimates.

Medication Switching Patterns

Among the 51,720 individuals who made medication category transitions during follow-up, treatment trajectories revealed substantial heterogeneity (Figure 6). The majority of transitions occurred between second-generation antipsychotics (68% of all transitions). Discontinuation events accounted for 22% of all transitions, with patients moving from medicated to unmedicated states. Notably, 8.2% of the cohort received clozapine during follow-up, representing treatment change for individuals with treatment-resistant schizophrenia.



Figure 6: **Sankey diagram showing medication switching patterns among switchers (n=50,440).** Flow width proportional to number of transitions. Medication categories: first-generation only, second-generation only, clozapine, polypharmacy, and no AP use.

4. Discussion

4.1. Principal Findings

In this nationwide cohort of 65,630 individuals with schizophrenia spectrum disorders, we demonstrate that the impact of antipsychotic medication on vocational recovery is not static but

highly stage-dependent. Using a within-subject design that controlled for genetic and historic confounding, we found that medication is associated with reduced employment rates during the first 5 years of illness (HR≈0.90–0.95), but shifts to a neutral or protective role (HR=1.02) in the long-term maintenance phase (5+ years). Critically, standard between-subject competing risks analysis failed to detect these dynamics, yielding a misleading 'null' result (SHR=1.002).

4.2. The Hierarchy of Evidence: Why Within-Subject Models Matter

The stark discrepancy between our primary (within-subject) and secondary (between-subject) analyses offers a vital methodological lesson. The Fine-Gray model, which mirrored the design of many traditional observational studies, suggested no relationship between treatment and outcome. However, this model is vulnerable to confounding by indication which is the clinical reality that patients with more severe illness (and lower employment potential) are more likely to be prescribed antipsychotics. This selection bias drags the estimate toward the null, masking any potential benefit or obscuring true harm.

By contrast, our within-subject Cox model eliminates this bias by comparing each patient to themselves during 'on' and 'off' medication periods. The fact that this more rigorous model unveiled a negative association in the early years suggests that the 'null' finding in the standard model was an artifact. We conclude that for etiological questions in schizophrenia, where unmeasured confounding is pervasive, within-subject designs should be prioritised over standard cohort comparisons (Hernán, 2010; Wolbers et al., 2009; Lau et al., 2017).

4.3. Clinical Implications: A Stage-Specific Approach

The 'J-curve' effect observed in our primary analysis, illustrated by an initial reduction in employment followed by long-term stabilisation, challenges the 'one-size-fits-all' approach to vocational recovery.

In the consolidation phase (2-5 years) the negative association (HR=0.946) is clinically significant. It suggests that once the acute crisis has passed, the sedative or motivational side effects of continuous antipsychotic treatment may hinder reintegration into the workforce. This 2–5 year window represents a critical 'missed opportunity' where intensive vocational rehabilitation or dosage optimisation is most needed to counteract medication-related functional dampening.

During the maintenance phase (5+ Years) the reversal to a positive association (HR=1.019) affirms current guidelines for long-term maintenance. For patients with chronic illness courses, medication appears to provide the stability required to sustain employment, or at minimum, ceases to be a barrier.

4.4. Comparison with Prior Studies

Our within-subject findings contrast with prior work. Solmi et al. (2022) found antipsychotic treatment associated with 30–50% lower risk of work disability (HR≈0.65) in Swedish patients with first-episode nonaffective psychosis, with long-acting injectables showing strongest protective associations. Similarly, Matsuzaki et al. (2023) reported higher employment during clozapine treatment using a mirror-image design. Holm et al. (2021) documented low baseline employment rates (24% for schizophrenia) in Nordic populations, consistent with our 33.4% at diagnosis. Our more granular time-stratified approach reveals that these averaged effects may obscure important temporal heterogeneity: medication effects vary substantially across the recovery trajectory.

4.5. Strengths and Limitations

Our study's primary strength is the integration of SMR hospital pharmacy data (correcting 6.1% exposure misclassification) combined with the statistical power of 26.9 million person-weeks and a rigorous within-subject design that controls for all time-invariant confounders.

The major limitation of the Fine-Gray analysis was its inability to accommodate time-varying covariates or within-subject stratification, rendering it a descriptive rather than causal tool in this context. Additionally, while the within-subject design controls for time-invariant confounders, it cannot adjust for time-varying symptom fluctuations (e.g., a relapse triggering both job loss and medication restart), potentially creating reverse causation bias. However, our lagged exposure sensitivity analyses (Figure 4) suggest this bias does not fully explain the findings, as negative associations persisted across 6, 12, and 24-month lag periods. The DREAM employment classification may misclassify ambiguous situations (fleksjob, parental leave, educational activation). Finally, Denmark's universal healthcare system may limit generalisability.

4.6. Conclusion

Antipsychotic medication is neither purely beneficial nor purely harmful for functional outcomes; its impact evolves with the stage of illness. While standard cohort analyses may suggest a 'null' effect, rigorous within-subject modelling reveals a transient trade-off: early-phase treatment serves as a stabiliser that may temporarily constrain vocational capacity before supporting long-term maintenance. Clinical practice should move toward stage-matched rehabilitation, with a specific focus on supporting employment during the 'consolidation' years (2–5 post-diagnosis) when the tension between symptom control and functional recovery is most acute.

5. Contributions (CRediT)

Conceptualisation - RT, ODH, ML, MN, MO Data curation - MO, FHG Formal analysis - RT, MO, CH Methodology - RT, FHG, OH, ML, MN, MO Software - RT, FHG, MO Supervision - MO Validation - MO, FHG Visualisation - RT Writing – original draft - RT Writing – review & editing - RT, FHG, CH, ODH, ML, MN, MO

RT, FHG, CH, MN and MO had access to the data.

6. Funding

No funding directly supported this research, however Danmarks Nationalbank funded the research visit that made this collaboration possible.

7. Acknowledgements

Thank you to Mathilde Werborg Birkholm and Aleksander Søltoft-Jensen for help with coding. Special thanks to Janne Petersen for making me part of the team. This research was made possible by Danmarks Nationalbank.

8. Declaration of Generative AI and AI-assisted technologies in the writing process

During the preparation of this work the authors used Claude Sonnet 4.5 (Anthropic, San Francisco: CA) to edit and plan the manuscript. After using this tool, the authors reviewed and edited the content as needed and take full responsibility for the content of the published article.

References

Ajnakina, O., Stubbs, B., Francis, E., Gaughran, F., David, A., Murray, R., Lally, J., 2021. Employment and relationship outcomes in first-episode psychosis: A systematic review and meta-analysis of longitudinal studies. Schizophrenia Research 231, 122–133. doi:10.1016/j.schres.2021.03.013.

Andersen, M.A., Jensen, T.L., Petersen, T.S., 2024. Data resource profile: The danish national hospital medicine register. Pharmacoepidemiology and Drug Safety 33, e70054. URL: https://doi.org/10.1002/pds.70054, doi:https://doi.org/10.1002/pds.70054.

Austin, P.C., Fine, J.P., 2017. Practical recommendations for reporting fine-gray model analyses for competing risk data. Statistics in Medicine 36, 4391–4400. doi:10.1002/sim.7501.

Benjamini, Y., Hochberg, Y., 1995. Controlling the false discovery rate: a practical and powerful approach to multiple testing. Journal of the Royal Statistical Society: Series B (Methodological) 57, 289–300.

Cornblatt, B.A., Carrion, R.E., Addington, J., Seidman, L., Walker, E.F., Cannon, T.D., Cadenhead, K.S., McGlashan, T.H., Perkins, D.O., Tsuang, M.T., Woods, S.W., Heinssen, R., Lencz, T., 2011. Risk factors for psychosis: Impaired social and role functioning. Schizophrenia Bulletin 38, 1247–1257. URL: https://academic.oup.com/schizophreniabulletin/article-abstract/38/6/1247/1858094, doi:https://doi.org/10.1093/schbul/sbr136.

Fine, J.P., Gray, R.J., 1999. A proportional hazards model for the subdistribution of a competing risk. Journal of the American Statistical Association 94, 496–509. doi:10.1080/01621459.1999.10474144.

Hernán, M.A., 2010. The hazards of hazard ratios. Epidemiology 21, 13–15. doi:10.1097/EDE.0b013e3181c1ea43.

Hjollund, N.H., Larsen, F.B., Andersen, J.H., 2007. Register-based follow-up of social benefits and other transfer payments: accuracy and degree of completeness in a danish interdepartmental administrative database compared with a population-based survey. Scandinavian Journal of Public Health 35, 497–502. URL: https://doi.org/10.1080/14034940701271882, doi:10.1080/14034940701271882.

Holm, M., Taipale, H., Tanskanen, A., Tiihonen, J., Mittendorfer-Rutz, E., 2021. Employment among people with schizophrenia or bipolar disorder: A population-based study using nationwide registers. Acta Psychiatrica Scandinavica 143, 61–71. doi:10.1111/acps.13254.

Jensen, T.B., Andersen, J.T., Jimenez-Solem, E., Lund, M., 2020. How patients in denmark acquire their medicines: overview, data sources and implications for pharmacoepidemiology. Basic Clinical Pharmacology & Toxicology 128, 46–51. doi:https://doi.org/10.1111/bcpt.13472.

Kassambara, A., Kosinski, M., Biecek, P., 2021. survminer: Drawing survival curves using 'ggplot2' URL: https://CRAN.R-project.org/package=survminer. r package version 0.4.9.

Keepers, G.A., Fochtmann, L.J., Anzia, J.M., Benjamin, S., Lyness, J.M., Mojtabai, R., Servis, M.E., Walaszek, A., Buckley, P., Lenzenweger, M.F., et al., 2020. The american psychiatric association practice guideline for the treatment of patients with schizophrenia. American Journal of Psychiatry 177, 868–872. doi:10.1176/appi.ajp.2020.177901.

Lau, B., Cole, S.R., Gange, S.J., 2017. Competing risk regression models for epidemiologic data. American Journal of Epidemiology 170, 244–256. doi:10.1093/aje/kwp107.

Lawlor, D.A., Tilling, K., Davey Smith, G., 2017. Triangulation in aetiological epidemiology. International Journal of Epidemiology 45, 1866–1886. doi:10.1093/ije/dyw314.

Leucht, S., Tardy, M., Komossa, K., Heres, S., Kissling, W., Salanti, G., Davis, J.M., 2012. Antipsychotic drugs versus placebo for relapse prevention in schizophrenia: a systematic review and meta-analysis. The Lancet 379, 2063–2071. doi:10.1016/S0140-6736(12)60239-6.

Lynge, E., Sandegaard, J.L., Rebolj, M., 2011. The Danish National Patient Register. Scandinavian Journal of Public Health 39, 30–33. doi:10.1177/1403494811401482.

Matsuzaki, H., Hatano, M., Iwata, M., Saito, T., Yamada, S., 2023. Effectiveness of clozapine on employment outcomes in treatment-resistant schizophrenia: A retrospective bidirectional mirror-image study. Neuropsychiatric Disease and Treatment 19, 615–622. doi:10.2147/NDT.S402945.

Moncrieff, J., Crellin, N., Stansfeld, J., Cooper, R., Marston, L., Freemantle, N., Lewis, G., Hunter, R., Johnson, S., Barnes, T., Morant, N., Pinfold, V., Smith, R., Kent, L., Darton, K., Long, M., Horowitz, M., Horne, R., Vickerstaff, V., Jha, M., 2023. Antipsychotic dose reduction and discontinuation versus maintenance treatment in people with schizophrenia and other recurrent psychotic disorders in england (the radar trial): an open, parallel-group, randomised controlled trial. The Lancet Psychiatry 10, 848–859. URL: https://www.thelancet.com/journals/lanpsy/article/PIIS2215-0366(23)00258-4/fulltext, doi:https://doi.org/10.1016/s2215-0366(23)00258-4.

Nordfalk, F., Hoeyer, K., 2017. The rise and fall of an opt-out system. Scandinavian Journal of Public Health 48, 400–404. URL: https://pubmed.ncbi.nlm.nih.gov/29207930/, doi:https://doi.org/10.1177/1403494817745189.

Pedersen, P., Olsen, B.B., Vernal, D.L., Rydborg, M.P., Gasse, C., Mors, O., 2025. Vocational rehabilitation in young adults with incident schizophrenia—a danish retrospective cohort study. Early Intervention in Psychiatry 19, e70062. URL: https://onlinelibrary.wiley.com/doi/abs/10.1111/eip.70062, doi:https://doi.org/10.1111/eip.70062, arXiv:https://onlinelibrary.wiley.com/doi/pdf/10.1111/eip.70062. e70062 EIP-2024-279.R1.

Plana-Ripoll, O., Liu, X., Köhler-Forsberg, O., Sørensen, H.T., Momen, N.C., 2025. Mental disorders in danish hospital registers: A review of content and possibilities for epidemiological research. Clinical Epidemiology Volume 17, 387–407. URL: https://pubmed.ncbi.nlm.nih.gov/40260425/, doi:https://doi.org/10.2147/clep.s509147.

Pottegård, A., Schmidt, S.A.J., Wallach-Kildemoes, H., Sørensen, H.T., Hallas, J., Schmidt, M., 2017. Data resource profile: The danish national prescription registry. International

Journal of Epidemiology 46, 798–798f. URL: https://doi.org/10.1093/ije/dyw213, doi:10.1093/ije/dyw213.

Schoenfeld, D., 1982. Partial residuals for the proportional hazards regression model. Biometrika 69, 239–241. doi:https://doi.org/10.1093/biomet/69.1.239.

Solmi, M., Taipale, H., Holm, M., Tanskanen, A., Mittendorfer-Rutz, E., Correll, C.U., Tiihonen, J., 2022. Effectiveness of antipsychotic use for reducing risk of work disability: Results from a within-subject analysis of a swedish national cohort of 21,551 patients with first-episode nonaffective psychosis. American Journal of Psychiatry 179, 938–946. doi:10.1176/appi.ajp.21121189.

Stürup, A.E., Nordentoft, M., Jimenez-Solem, E., Osler, M., Davy, J.W., Christensen, T.N., Speyer, H., Albert, N., Hjorthøj, C., 2023. Discontinuation of antipsychotics in individuals with first-episode schizophrenia and its association to functional outcomes, hospitalization and death: a register-based nationwide follow-up study. Psychological Medicine 53, 5033–5041. doi:https://doi.org/10.1017/s0033291722002021.

Therneau, T., Crowson, C., Atkinson, E., 2017. Using Time Dependent Covariates and Time Dependent Coefficients in the Cox Model. URL: https://people.math.aau.dk/~rw/Undervisning/DurationAnalysis/Literature/timedep_therneau.pdf.

Therneau, T.M., 2024. A package for survival analysis in r URL: https://CRAN.R-project.org/package=survival. r package version 3.5-8.

Tiihonen, J., Haukka, J., Taylor, M., Haddad, P.M., Patel, M.X., Korhonen, P., 2011. A nationwide cohort study of oral and depot antipsychotics after first hospitalization for schizophrenia. American Journal of Psychiatry 168, 603–609. URL: https://doi.org/10.1176/appi.ajp.2011.10081224, doi:10.1176/appi.ajp.2011.10081224.

Twumasi, R., Lange, M., Hjorthøj, C., Howes, O., Gronemann, F.H., Nordentoft, M., Osler, M., 2025. Protocol for: Association of antipsychotic medication usage and employment outcomes in patients with schizophrenia spectrum disorders: A danish register-based study. URL: https://www.medrxiv.org/content/medrxiv/early/2025/10/03/2025.10.02.25337161.full.pdf, doi:10.1101/2025.10.02.25337161. pre-print.

WHO, 2025. Atc classification index with ddds (atc/ddd index 2025). URL: https://atcddd.fhi.no/atc_ddd_index/. accessed 2025-10-01. Annual updates are issued each January.

Wolbers, M., Koller, M.T., Witteman, J.C., Steyerberg, E.W., 2009. Competing risks analyses: objectives and approaches. European Heart Journal 35, 2936–2941. doi:10.1093/eurheartj/ehu131.

Wunderink, L., Nieboer, R.M., Wiersma, D., Sytema, S., Nienhuis, F.J., 2013. Recovery in remitted first-episode psychosis at 7 years of follow-up of an early dose reduction/discontinuation or maintenance treatment strategy. JAMA Psychiatry 70, 913. doi:10.1001/jamapsychiatry.2013.19.

Appendix A. Supplementary Table 1: Operationalisation of Analytical Categories

Category	Label	DREAM Benefit Codes
Primary Outcome: Productive Engagement (Categories 3 and 10)		
10	Employment	No benefit code (blank/NA indicates labour market attachment)
3	Education & Vocational Training	211–219, 231, 232, 299, 412, 413, 511, 521, 522, 651, 652, 661
Non-Productive States		
1	Sickness & Temporary Incapacity	890–899
2	Unemployment & Job-Seeking	111–113, 115, 121–140, 143–153, 160–169
4	Social Assistance & Rehabilitation	740–781
5	Retirement & Pension Benefits	621, 622, 783, 784, 810, 819, 870, 879, 881, 996, 998
Censoring Events		
6	Emigration	997
7	Death	999



Figure A.7: Sankey diagram illustrating censoring flow patterns over 10-year follow-up (n=65,630 patients). Flow width proportional to number of individuals.



Figure A.8: **[Supplementary Figure 1]** Cox proportional hazards forest plot of 'conditional success rate' for productive engagement (overall models pooling across time). Hazard ratios with 95% confidence intervals from within-person stratified models (n=50,440 switchers, 21.2 million person-weeks). Model 1: Any antipsychotic use versus none (HR=1.08, p<0.001). Model 2: Polypharmacy versus monotherapy/none (HR=0.70, p<0.001). Dashed vertical line indicates null effect (HR=1.0).

STROBE Statement: Checklist of Items for Cohort Studies

Item	Recommendation	Reported	Page
Title and Abstract			
1(a)	Indicate study design with commonly used term	"Register-based cohort study" in title and abstract	1
1(b)	Provide informative, balanced summary	Abstract provides background, methods, results, interpretation	1
Introduction			
2	Explain scientific background and rationale	Background on antipsychotics, employment, existing evidence gaps	2
3	State specific objectives including prespecified hypotheses	Objectives stated; protocol pre-registered on medRxiv	2–3
Methods			
4	Present key elements of study design	Nationwide cohort, within-subject design, 1998–2023	3
5	Describe setting, locations, relevant dates	Denmark; diagnosis dates 1998–2023; follow-up to 2023	3
6(a)	Give eligibility criteria, sources/methods of selection	First F20–F29 diagnosis; Danish National Patient Register	3
6(b)	For matched studies, give matching criteria and number	Within-subject design; each patient serves as own control	4
7	Define outcomes, exposures, predictors, confounders	Productive engagement (DREAM codes); antipsychotic exposure (N05A); covariates defined	4–5
8	Describe data sources and measurement methods	Danish registers: NPR, DREAM, SMR; ICD-10; ATC codes	3–4
9	Describe efforts to address potential bias	Within-subject design controls time-invariant confounding; competing risks models	4–5
10	Explain how study size was arrived at	All eligible individuals in national registers; N=65,630	6
11	Explain how quantitative variables were handled	Time-varying binary exposure; person-week observations	4–5
12(a)	Describe all statistical methods	Cox models, Fine-Gray, time-stratification, lagged analyses	4–5
12(b)	Describe methods for examining subgroups/interactions	Time-stratified by period; medication type subgroups	5
12(c)	Explain how missing data were addressed	Complete linkage via CPR; DREAM has no missing benefit data	3
12(d)	Describe analytical methods for loss to follow-up	2-year landmark; death/emigration as competing events	3, 5
12(e)	Describe sensitivity analyses	Lagged exposure; SMR integration; time-stratification	5
Results			
13(a)	Report numbers at each stage of study	65,630 included; 1,000 excluded (2-year filter); flow described	6
13(b)	Give reasons for non-participation at each stage	Death/emigration within 2 years; see Methods	3

Continued on next page...

Item	Recommendation	Reported	Page
13(c)	Consider use of flow diagram	Sankey diagrams for censoring and medication transitions	Supp.
14(a)	Give characteristics of participants	Table 1: demographics, diagnosis, baseline employment	6–7
14(b)	Indicate number with missing data for each variable	Complete data due to mandatory register linkage	3
15	Report numbers of outcome events or summary measures	26.9 million person-weeks; 48.2% engagement rate; event counts	6–8
16(a)	Give unadjusted and adjusted estimates	Time-stratified HRs with CIs; Fine-Gray SHR	7–10
16(b)	Report category boundaries for continuous variables	Age groups in Table 1; time periods defined	6–7
16(c)	Consider translating relative to absolute risk	Absolute engagement rates by medication type provided	8
17	Report other analyses performed	Lagged effects; SMR sensitivity; dose-response	9–11
Discussion			
18	Summarise key results with reference to objectives	Null Fine-Gray result; temporal heterogeneity in Cox	12
19	Discuss limitations including bias sources	Time-varying confounding; adherence measurement; generalisability	13
20	Give cautious interpretation considering objectives and limitations	Medication as marker vs driver; vocational intervention timing	12–13
21	Discuss generalisability (external validity)	Danish welfare context; universal healthcare; may differ elsewhere	13
Other Information			
22	Give source of funding and role of funders	No direct funding, Danmarks Nationalbank funded research visit; no role in study conduct	1